$BOLD News

Boundless Bio Q1 EPS $(0.60) Beats $(0.64) Estimate

Boundless Bio Reveals Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting

Boundless Bio: An Underestimated Biotech With A First-In-Class EcDNA Targeted Kinesin Degrader

Boundless Bio Announces Upcoming Presentation of Oral Kinesin Degrader Program at the American Association for Cancer Research Annual Meeting 2026

Boundless Bio To Present Oral Kinesin Degrader Program At The AACR Annual Meeting 2026

Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

Boundless Bio Q4 EPS $(0.58) Misses $(0.52) Estimate

Boundless Bio to Participate in the Leerink Global Healthcare Conference

Boundless Bio, Inc. (BOLD) Upgraded to Buy: Here's Why

Boundless Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

We're Keeping An Eye On Boundless Bio's (NASDAQ:BOLD) Cash Burn Rate

Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway

Trading Halt: Halt status updated at 7:25:00 AM ET: Quotation Resumption: News and Resumption Times

Trading Halt: Halt status updated at 7:25:00 AM ET: Quotation Resumption: News and Resumption Times

The FDA Accepts Boundless Bio's Investigational New Drug Application for BBI-940; Also, the Company Will Cease Enrollment in Phase 1/2 POTENTIATE Trial of BBI-355 Combined With BBI-825 in Oncogene-amplified Cancers

Trading Halt: Halted at 6:55:00 a.m. ET - Trading Halt: Halt News Pending

Boundless Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference

Boundless Bio Reports Third Quarter 2025 Financial Results and Business Highlights

Boundless Bio Q3 EPS $(0.62) Misses $(0.53) Estimate

Boundless Bio Announces Upcoming Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics